GnRH Agonist Therapy in a Patient with Recurrent Ovarian Granulosa Cell Tumors.
10.3346/jkms.2009.24.3.535
- Author:
Hyun Jung KIM
1
;
Sang Cheol LEE
;
Sang Byung BAE
;
Kye Won KWON
;
Chan Kyu KIM
;
Nam Su LEE
;
Kyu Taek LEE
;
Jong Ho WON
;
Dae Sik HONG
;
Hee Sook PARK
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon Hospital, Bucheon, Korea. dshong@schbc.ac.kr
- Publication Type:Case Report
- Keywords:
Granulosa Cell Tumor;
Hormone Therapy;
Leuprolide
- MeSH:
Aged;
Antineoplastic Agents, Hormonal/*therapeutic use;
Female;
Gonadotropin-Releasing Hormone/*agonists/metabolism;
Granulosa Cell Tumor/diagnosis/*drug therapy/radiography;
Humans;
Leuprolide/*therapeutic use;
Ovarian Neoplasms/diagnosis/*drug therapy/radiography;
Recurrence
- From:Journal of Korean Medical Science
2009;24(3):535-538
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 65-yr-old woman presented 17 yr status post-hysterectomy with bilateral ovarian salpingo-oophorectomy, attributable to ovarian cancer. She was admitted to our hospital, with multiple cystic liver masses and multiple large seeded masses in her abdomen and pelvic cavity. Histological examination of the pelvic masses demonstrated granulosa cell tumors. After two courses of systemic combination chemotherapy, with paclitaxel and carboplatin, the masses in the abdomen and pelvic cavity increased, and debulking surgery also failed because of peritoneal dissemination with severe adhesion. Finally, she underwent palliative radiotherapy for only the pelvic masses obstructing the urinary and GI tracts, and monthly hormonal therapy with a gonadotrophin-releasing hormone agonist; leuprorelin 3.75 mg IM. Subsequently, multiple masses beyond the range of the radiation as well as those within the radiotherapy field partially decreased. This partial response had been maintained for more than 8 months as of the last follow-up visit. Owing to its long and indolent course and the low metabolic rate of the tumors, advanced or recurrent granulosa cell tumor (GCT) requires treatment options beyond chemotherapy, surgery, and radiotherapy. Hormonal agents may provide another treatment option for advanced or recurrent GCT in those who are not candidates for surgery, chemotherapy, or radiotherapy.
